Wanda Salyer
Psychiatric/Mental Health · Columbus, GANPI 1578226502
Payments from drug & device makers
Across 138 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$415
- Corium, LLC$351
- AbbVie$313
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$294
- Teva Pharmaceuticals USA, Inc.$222
- Alkermes, Inc.$205
- plus $945 from 12 others
What the payments were for
- Food & beverage$2,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $415 |
| Corium, LLC | 15 | $351 |
| AbbVie | 19 | $313 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $294 |
| Teva Pharmaceuticals USA, Inc. | 12 | $222 |
| Alkermes, Inc. | 11 | $205 |
| Johnson & Johnson | 7 | $166 |
| Lundbeck LLC | 8 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $119 |
| Vanda Pharmaceuticals Inc. | 5 | $109 |
| Collegium Pharmaceutical, Inc. | 5 | $104 |
| Neurocrine Biosciences, Inc. | 4 | $101 |
| Vertical Pharmaceuticals, LLC | 3 | $51 |
| Tris Pharma Inc | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Biogen | 1 | $23 |
| Neos Therapeutics, LP | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,746 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Pamoate | 32 | $200 |
| Quetiapine Fumarate | 11 | $189 |
| Trazodone Hcl | 25 | $64 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Columbus
- Caroline LukanoColumbus$4K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.